Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo‐Controlled, Phase II Trial

• Main Authors: Tessa Niemeyer‐van der Kolk (Author), Hein van derWall (Author), Geretta K. Hogendoorn (Author), Rianne Rijneveld (Author), Sascha Luijten (Author), Dirk C.J.G. vanAlewijk (Author), Ellen H.A. van denMunckhof (Author), Marieke L. deKam (Author), Gary L. Feiss (Author), Errol P. Prens (Author), Jacobus Burggraaf (Author), Robert Rissmann (Author), Martijn B.A. vanDoorn (Author)
• Format: Book
• Published: Wiley, 2020-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Omiganan is an indolicidin analog with antimicrobial properties that could be beneficial for patients with atopic dermatitis. In this randomized, double‐blind, placebo‐controlled, phase II trial we explored the efficacy, pharmacodynamics, and safety of topical omiganan once daily in 36 patients with...